Treatment of Youth With ADHD and Anxiety

• Status: Completed
• Trial end date: 2002-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this NIMH-sponsored pilot study is to collect information on the efficacy and safety of drug treatments for children and adolescents who suffer from both ADHD and anxiety disorders. Specifically, the study will examine the benefits of the stimulant medication both alone and in combination with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that has antianxiety effects. Young people aged 6 to 17 diagnosed with these co-occurring disorders may be eligible to participate.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Mental Health (NIMH)
• Treatments: Fluvoxamine; Methylphenidate

Criteria

• ADHD diagnosis

• DSM-IV diagnosis of anxiety

• IQ greater than 70

• residence with primary caretaker for at least 6 months

• ages 6-17 and attending school

• no previous treatment failure to or intolerance of fluvoxamine or methylphenidate (unless currently taking another stimulant)